Mingyuan Medicare Announces Collaboration with CHGC and SBC on...

Mingyuan Medicare Announces Collaboration with CHGC and SBC on Major Infectious Diseases Detecting Platform in Fight Against Human Swine Flu

The Board of Mingyuan Medicare Development Company Limited ("Mingyuan Medicare" or the "Company", Stock code: 0233) is pleased to announce today that the Company had entered into a milestone co-operation agreement (the "Co-operation Agreement") with Chinese National Human Genome Centre in Shanghai ("CHGC") and Shanghai Biochip Company Limited ("SBC") on the joint establishment of an uniquely dynamic technology platform with rapid response capability to develop diagnostic kits for early detection of major or new infectious diseases on demand basis. The platform is important for the industrialization of high-tech national medical products.

The two products above are able to qualitatively detect new Influenza A/H1N1 virus, seasonal Influenza A H1 virus and Non-A H1 Influenza virus and identify with fluorescent labels, being applicable to respiratory tract sample test (nasopharynx swab / aspirate or nasal cavity wash / aspirate). The diagnostic kits are able to detect Influenza A viruses at a very early stage of infection. As the test result is available in 2 hours, the kits can be used in hospitals, border checkpoints and clinics to help diagnose suspected symptomatic and asymptomatic infections and thus effectively prevent the virus from further spreading.

Mr. Henry Chien, CEO of Mingyuan Medicare, said, "We are honoured to be a partner of CHGC and SBC. The technology platform with rapid response capability to develop diagnostic kits for early detection of major or new infectious diseases is believed to play an important role in the development of human health. Currently, Influenza A viruses (including the recent outbreak of Influenza A (H1N1) virus) is a highly infectious disease which has long been regarded as a major health hazard to human. Furthermore, the World Health Organization may soon raise the influenza pandemic alert level from Phase 5 to Phase 6, the highest pandemic phase. The two newly-developed advanced diagnostic kits for detecting Influenza A viruses help to identify Human Swine Flu (A H1N1) patients, and this is believed to be critical to effectively preventing the spread of the infectious disease and to improve the chance of recovery."

The State Council published Certain Policies to Promote Bio-industry Development aiming at building bio industry into pillars of high-tech sector and new strategic sector of China. Many policies such as supporting the development of biomedical sector and preferential taxation will facilitate the industrialization of high-tech medical products and rapid development of the industry. As the leader of the biomedical industry, Mingyuan Medicare is the first to benefit from such supportive policies. At the same time, Mingyuan Medicare has been attracting investment from world-renowned companies such as the strong and prominent CCBI. It has also established mutually beneficial commercial partnership with China Life, the insurance company in China with the largest market share, and GE (China) Co., Ltd. Healthcare, the leader in the healthcare industry. These moves clearly demonstrate the Companys strengths and prospects.

Moreover, the Company recently acquired Genetel BVI as well as 75% equity interest in Shanghai Kang Pei Bio-Medical Company Limited, which further strengthen the Company's DNA technology and products whilst expanding its health check services and network of medical centres.

About Chinese National Human Genome Centre in Shanghai

Chinese National Human Genome Centre in Shanghai (CHGC) is a national research centre established in 1998 for fulfilling the national scientific projects of human genome research and its application and development for China. CHGC was founded by many established institutes from the related biotech fields in Shanghai and the relevant government agencies including the Chinese Ministry of Science and Technology, Shanghai Municipal Government and Chinese Academy of Sciences ("CAS"). Visit www.chgc.sh.cn/en/.

About Shanghai Biochip Company Limited

Founded in 2001, Shanghai Biochip Company Limited ("SBC") is one of the largest biotech companies in China and is also the National Engineering Center for biochip design and engineering in Shanghai. Facilitated with advanced biotech platforms and labs and operated by strong teams for research, services, marketing and sales, SBC provides a series of biochips and related technical services, proprietary drug targets and relevant diagnostic products. SBC is funded by the Chinese government and was founded by eleven shareholders including the Shanghai Institute for Biological Sciences of CAS and other shareholders consisting of all top academic universities, research institutes, hospitals, and leading biotech companies in China. Visit www.shbiochip.com.

About Mingyuan Medicare

Mingyuan Medicare Development Company Limited (stock code: 0233) was listed in September 2002 on the Main Board of the Stock Exchange of Hong Kong. It is one of the best biotechnology and healthcare companies in the PRC, principally engaged in provision of innovative medicare solutions for the early detection and prevention of diseases particularly in China. With "Care for Health, Passion for Life" as its motto, the Company dedicates to the development and application of advanced biotech screening and diagnostic solutions for early detection and prevention of diseases including cancer. With fast growth and product diversification, the Company takes a dominant position in disease detection. According to the research report of an investment bank, the Company takes an absolute advantage and has no close competitors in cancer detection technology applied in domestic insurance policies. In addition to diagnostic kits for detecting Influenza A viruses, its products include the proprietary protein chip system for multi-tumor marker detection (C-12), patented HPV DNA screening product for cervical cancer and screening chips for pulmonary tuberculosis. The Company aspires to become a manufacturer and service provider with the largest capacity in sophisticated biomedical products based on biochip technology in China and the world. Visit www.mingyuan-hk.com.

This press release is issued by Wonderful Sky Financial Group Limited on behalf of Mingyuan Medicare Development Company Limited.

Source from ACN Newswire